Card image cap
FDA clears cilta-cel as new multiple myeloma treatment

The US FDA has approved a new treatment option– ciltacabtagene autoleucel (cilta-cel)– for patients with refractory or relapsed multiple myeloma and who have already tried four or more therapies. The new drug, marketed as Carvykti by Janssen and Legend Biotech, is a chimeric antigen receptor (CAR) T-cell therapy directed against B-cell maturation antigen (BCMA), and a new target for therapies for multiple myeloma.

Source: medscape

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Supported by Koye Pharmaceuticals

Submit a Comment